Health
FDA grants rare disease designations to investigational brain tumor drug – News-Medical.Net
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahom…
Reviewed by Emily Henderson, B.Sc.Sep 2 2020
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
DIPG is a fast-growing pediatric cancer that starts in the brain stem. It is one of several sub-categories of malignant gliomas,…
-
Noosa News21 hours agoElectrify your vehicle, home or business at Noosa’s EV & Electrify Everything Expo
-
General17 hours agoCanberra man accused of flashing and assaulting 12-year-old girl released on bail
-
Noosa News19 hours agoDrought pushes farmers’ mental health to the brink across southern Australia
-
Noosa News19 hours agoQueensland plan to increase lethal shark control measures goes against advice of government-commissioned report